{"entity":{"id":"telik","kind":"company","name":"Telik","aka":["Telik, Inc."],"tldr":"Telik was a Palo Alto biotech whose glutathione analogue canfosfamide (Telcyta) failed its phase 3 trials in ovarian and lung cancer in the 2000s, a reminder that late-stage failure is the norm in oncology.","summary":"Telik, Inc., founded in 1988 in Palo Alto, California, developed canfosfamide (TLK286, Telcyta), a prodrug activated by glutathione S-transferase P1-1 that is overexpressed in many tumours. It led phase 3 trials in platinum-resistant ovarian cancer and non-small cell lung cancer, none of which met their primary endpoints, and the company later wound down its programmes. Its trials remain on ClinicalTrials.gov under Telik as lead sponsor.","asOf":"2026-09-11","links":[{"label":"Official website","url":"http://telik.com"},{"label":"ClinicalTrials.gov: trials led by Telik, Inc.","url":"https://clinicaltrials.gov/search?lead=Telik%2C%20Inc."},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q17146330"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["ovarian","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Palo Alto, CA","country":"US","companyType":"biotech","website":"http://telik.com","founded":1988,"stage":"defunct","investors":[],"funding":[]},"route":"/companies/telik/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}]}}